Assembly Biosciences - 14 Year Stock Price History | ASMB

Historical daily share price chart and data for Assembly Biosciences since 2010 adjusted for splits and dividends. The latest closing stock price for Assembly Biosciences as of October 31, 2024 is 16.81.
  • The all-time high Assembly Biosciences stock closing price was 1215.00 on May 09, 2011.
  • The Assembly Biosciences 52-week high stock price is 19.93, which is 18.6% above the current share price.
  • The Assembly Biosciences 52-week low stock price is 7.70, which is 54.2% below the current share price.
  • The average Assembly Biosciences stock price for the last 52 weeks is 13.28.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Assembly Biosciences Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2024 14.0429 9.9840 19.4300 9.5688 16.8100 70.81%
2023 12.6612 16.0800 20.8800 7.7676 9.8412 -36.92%
2022 21.4465 29.4000 29.4000 13.0800 15.6000 -44.21%
2021 47.3995 72.4800 79.5600 25.5600 27.9600 -61.49%
2020 204.0138 238.8000 324.4800 58.4400 72.6000 -70.43%
2019 194.0036 276.4800 299.1600 100.3200 245.5200 -9.55%
2018 475.6879 555.3600 769.9200 228.6000 271.4400 -50.01%
2017 321.8113 146.2800 598.9200 146.2800 543.0000 272.43%
2016 89.6583 86.2800 169.8000 54.4800 145.8000 61.78%
2015 153.3181 94.5600 242.4000 87.8400 90.1200 -4.45%
2014 102.9797 225.6000 267.6000 51.6000 94.3200 -58.85%
2013 164.4384 143.4000 229.2000 123.0000 229.2000 76.85%
2012 389.8670 479.4000 754.8000 123.6000 129.6000 -73.03%
2011 641.0420 408.0000 1215.0000 360.0000 480.4800 20.97%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.107B $0.007B
Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.590B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00